CN101631783A - 晶体盐酸度洛西汀 - Google Patents

晶体盐酸度洛西汀 Download PDF

Info

Publication number
CN101631783A
CN101631783A CN200780023170A CN200780023170A CN101631783A CN 101631783 A CN101631783 A CN 101631783A CN 200780023170 A CN200780023170 A CN 200780023170A CN 200780023170 A CN200780023170 A CN 200780023170A CN 101631783 A CN101631783 A CN 101631783A
Authority
CN
China
Prior art keywords
duloxetine hydrochloride
solution
crystalline duloxetine
organic
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780023170A
Other languages
English (en)
Chinese (zh)
Inventor
姜维平
贾春荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Shenghuaxi Pharmaceutical Co Ltd
Arrow International Ltd
Original Assignee
Chongqing Shenghuaxi Pharmaceutical Co Ltd
Arrow International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Shenghuaxi Pharmaceutical Co Ltd, Arrow International Ltd filed Critical Chongqing Shenghuaxi Pharmaceutical Co Ltd
Publication of CN101631783A publication Critical patent/CN101631783A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CN200780023170A 2006-06-23 2007-06-21 晶体盐酸度洛西汀 Pending CN101631783A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0612509.0A GB0612509D0 (en) 2006-06-23 2006-06-23 Crystalline duloxetine hydrochloride
GB0612509.0 2006-06-23
GBGB0700830.3A GB0700830D0 (en) 2006-06-23 2007-01-16 Crystalline duloxetine hydrochloride
GB0700830.3 2007-01-16

Publications (1)

Publication Number Publication Date
CN101631783A true CN101631783A (zh) 2010-01-20

Family

ID=38510285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780023170A Pending CN101631783A (zh) 2006-06-23 2007-06-21 晶体盐酸度洛西汀

Country Status (10)

Country Link
US (1) US7795455B2 (cg-RX-API-DMAC7.html)
EP (1) EP2049512A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009541291A (cg-RX-API-DMAC7.html)
CN (1) CN101631783A (cg-RX-API-DMAC7.html)
AU (1) AU2007262800A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712372A2 (cg-RX-API-DMAC7.html)
CA (1) CA2655991A1 (cg-RX-API-DMAC7.html)
GB (2) GB0612509D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ572919A (cg-RX-API-DMAC7.html)
WO (1) WO2007148102A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172610A (zh) * 2011-12-23 2013-06-26 石药集团中奇制药技术(石家庄)有限公司 一种盐酸度洛西汀的制备方法
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术(石家庄)有限公司 一种盐酸度洛西汀晶型及其制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
CN113603673A (zh) * 2020-11-16 2021-11-05 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612509D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
US8278463B2 (en) 2008-04-04 2012-10-02 Ranbaxy Laboratories Limited Process for the preparation of pure duloxetine hydrochloride
CZ304602B6 (cs) * 2009-09-02 2014-07-30 Zentiva, K. S. Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
AU2003263585A1 (en) 2003-08-25 2005-03-10 Hetero Drugs Limited Amorphous duloxetine hydrochloride
US20050197503A1 (en) * 2004-03-05 2005-09-08 Boehringer Ingelheim International Gmbh Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
US7550605B2 (en) 2004-08-05 2009-06-23 Sun Pharmaceutical Industries Ltd. Process for preparation of an anitdepressant compound
CZ297560B6 (cs) 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
EP1812428A2 (en) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
WO2006058121A1 (en) 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
US20060270859A1 (en) * 2005-01-27 2006-11-30 Santiago Ini Duloxetine HCl polymorphs
US7534900B2 (en) 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
EP1976844A4 (en) * 2006-01-06 2010-11-03 Msn Lab Ltd IMPROVED METHOD FOR PURE DULOXETIN HYDROCHLORIDE
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
GB0612509D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172610A (zh) * 2011-12-23 2013-06-26 石药集团中奇制药技术(石家庄)有限公司 一种盐酸度洛西汀的制备方法
CN103172610B (zh) * 2011-12-23 2015-11-25 石药集团中奇制药技术(石家庄)有限公司 一种盐酸度洛西汀的制备方法
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术(石家庄)有限公司 一种盐酸度洛西汀晶型及其制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
CN113603673A (zh) * 2020-11-16 2021-11-05 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用
CN113603673B (zh) * 2020-11-16 2024-08-06 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用

Also Published As

Publication number Publication date
NZ572919A (en) 2012-01-12
EP2049512A2 (en) 2009-04-22
GB0612509D0 (en) 2006-08-02
JP2009541291A (ja) 2009-11-26
WO2007148102A2 (en) 2007-12-27
US7795455B2 (en) 2010-09-14
AU2007262800A1 (en) 2007-12-27
CA2655991A1 (en) 2007-12-27
US20080021091A1 (en) 2008-01-24
GB0700830D0 (en) 2007-02-21
WO2007148102A3 (en) 2008-03-13
BRPI0712372A2 (pt) 2012-06-12

Similar Documents

Publication Publication Date Title
JP5247687B2 (ja) 結晶塩酸デュロキセチン
EP2346850A1 (en) A method for the preparation of dabigatran and its intermediates
US7795455B2 (en) Crystalline duloxetine hydrochloride
US8093407B2 (en) Crystalline duloxetine hydrochloride
WO2007119114A2 (en) Improved synthesis and preparations of duloxetine salts
ZA200402191B (en) Muscarinic agonists.
JP2009541291A5 (cg-RX-API-DMAC7.html)
CN112739686B (zh) 用于制备(-)-西苯唑啉琥珀酸盐的新方法
JP2009541292A5 (cg-RX-API-DMAC7.html)
WO2010046360A1 (en) Process for the preparation of substantially optically pure repaglinide and precursors thereof
CN118324648A (zh) (r)-特布他林苯磺酸盐a晶型和b晶型及其制备方法
WO2011013632A1 (ja) チアベンゾアズレンプロピオン酸誘導体の製造法
WO2012085645A1 (en) Polymorphs of 3-chloro-4[(2r)-2
EP2177221A1 (en) Process for the preparation of substantially optically pure Repaglinide and precursors thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100120